hotspot -WSS

hotspot

author：entertainment 2025-10-01 00:46:02 - browse：9164

Why are addiction treatments so hard to get? Can small companies compete in obesity? And since when is “Series E” a thing in biotech?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots of venture capital, and the race to develop effective oral treatments for obesity.

For more on what we cover, here’s the story on addiction medicine; here’s the latest on biotech financing; here’s more on Novo Nordisk’s oral obesity treatment; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： iTeos Therapeutics debuts first data on TIGIT

WSS

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

How to save health care price transparency rules

Startling documents reveal new facets of Sacklers' opioid empire

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Dark money group runs ads on China biotech bill

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

entertainment

hotspot

entertainment

Psychedelics group wrestles with new pharma identity

Average age of first period drops to 11.9 years, study shows

ChatGPT in medicine: STAT answers readers' burning questions

David Sabatini, ex

At least 13 dead in Texas as scorching temps continue

Dark money group runs ads on China biotech bill

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare coverage of Wegovy, once blocked, now looks possible

At least 13 dead in Texas as scorching temps continue

Boston's new lab space is opening empty

focus

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Adam's Biotech Scorecard: Do Sarepta's exon

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Focused ultrasound for uterine fibroids: an uphill battle

leisure time

entertainment

hotspot

explore